← Back to Search

Stem Cell Transplantation

Allogeneic stem cell transplantation for Sarcoidosis

Phase 1 & 2
Waitlist Available
Led By Richard Burt, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up participants are to be followed at 6 months and then yearly until 5 years
Awards & highlights

Summary

Sarcoidosis is a disease believed to be due to immune cells, cells which normally protect the body, but are now attacking lungs, heart, nerves, or other organs or systems within the body. As a result, the affected organs or systems fail to work properly causing difficulty breathing; heart failure; inability of the nerves to respond properly causing numbing, tingling, pain, and progressive muscle weakness; or other symptoms depending on the organ or body system involved. The likelihood of progression of this disease is high. This study is designed to examine whether treating patients with high dose cyclophosphamide (a drug which reduces the function of the immune system) and ATG (a protein that kills the immune cells that are thought to be causing this disease), followed by return of the previously collected blood stem cells will stop the progression of sarcoidosis. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the high dose cyclophosphamide and ATG is to destroy the cells in the immune system. The purpose of the stem cell infusion is to evaluate whether this treatment will produce a normal immune system that will no longer attack the body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants are to be followed at 6 months and then yearly until 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and participants are to be followed at 6 months and then yearly until 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Presence of Toxicity
Survival
Time to Disease Progression

Trial Design

2Treatment groups
Experimental Treatment
Group I: Autologous hematopoietic stem cell transplantationExperimental Treatment1 Intervention
Autologous stem cells will be injected after conditioning
Group II: Allogeneic stem cell transplantationExperimental Treatment1 Intervention
Allogeneic stem cells will be injected after conditioning
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Autologous hematopoietic stem cell transplantation
2010
Completed Phase 2
~70
Allogeneic stem cell transplantation
2005
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,608 Previous Clinical Trials
927,315 Total Patients Enrolled
1 Trials studying Sarcoidosis
101 Patients Enrolled for Sarcoidosis
Richard Burt, MDPrincipal InvestigatorNorthwestern University
28 Previous Clinical Trials
527 Total Patients Enrolled
~0 spots leftby Sep 2025